Azilsartan Medoxomil: Angiotensin Receptor Blocker in the Treatment of Hypertension
International Journal of Medical and Dental Sciences, 2018 Hypertension is an important risk factor for cardiovascular and renal disease. It’s early detection and control is critically important as it is an important attributable cause of stroke, coronary artery disease, heart failure, atrial fibrillation and ESRD. Recent data indicates increasing prevalence of hypertension amongst various populations.
Megha Sood +2 more
openaire +2 more sources
Critical evaluation of the efficacy and tolerability of azilsartan
Vascular Health and Risk Management, 2012 Alberto R De Caterina1,2, Andrew R Harper2,3, Florim Cuculi21Istituto Scienze della Vita, Scuola Superiore Sant'Anna, Pisa, Italy; 2Oxford University Hospitals, Oxford; 3Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne ...
Cuculi F, Harper AR, De Caterina AR
doaj
Differential pharmacology and benefit/risk of azilsartan compared to other sartans
Vascular Health and Risk Management, 2012 Theodore W Kurtz1, Takashi Kajiya21Department of Laboratory Medicine, University of California, San Francisco, CA, USA ; 2Department of Cardiovascular, Respiratory, and Metabolic Medicine, Graduate School of Medicine, Kagoshima University, Kagoshima ...
Kurtz TW, Kajiya T
doaj
КардиоСоматика, 2015 The article discusses the problem of the use for the treatment of hypertension combination therapy. Advantages of application as a component of chlorthalidone therapy are discussed.
M. G Bubnova
doaj
GW27-e0799 Safety of azilsartan medoxomil in hypertension: A Meta-analysis
Journal of the American College of Cardiology, 2016 This study was to compare the safety in patients with hypertension receiving azilsartan medoxomil as monotherapy or other antihypertensive agents. The Cochrane library, PubMed, Chinese National Knowledge Infrastructure(CNKI), Wanfang Data were searched from the beginning of the records ...
Zhang Panxiao +3 more
openaire +1 more source
PROTECTION AND TOLERABILITY OF AZILSARTAN MEDOXOMIL IN RESPONDENTS WITH IMPORTANT HYPERTENSION
, 2020 The current 58-week, level 4, open-label, two-partner, successive, non-randomized study assessed well-being and poor quality of inessential hypertension due to azelastine minoxidil (AZL-M) (baseline mean blood pressure 152/100 mmHg). Altogether focuses (n¼669) began taking 42 mg QD of AZL-M, the potency was increased to 80 mg QD at week 5, whenever ...
openaire +1 more source
A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension. [PDF]
Medicine (Baltimore), 2020 Wu J +13 more
europepmc +1 more source
Azilsartan medoxomil/chlorthalidone – a new effective antihypertensive combination
Cardiology: News, Opinions, Training, 2022 E.K. Serezhina, A.G. Obrezan
openaire +1 more source
Efficacy and safety of different doses of azilsartan medoxomil in patients with hypertension: A protocol of a network meta-analysis. [PDF]
Medicine (Baltimore), 2019 Zhang Y +5 more
europepmc +1 more source
Use of azilsartan medoxomil in the primary-care setting in Germany: A real-world evidence study . [PDF]
Int J Clin Pharmacol Ther, 2019 Ehlken B +4 more
europepmc +1 more source